NK/T cell lymphoma
Conditions
Interventions
1:Anti-PD1+GEMOX
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria for study entry: 1. Aged 18 to 75 years, ECOG performance status of 0, 1, or 2, Life expectancy of >12 weeks; 2. All patents are diagnosed as R/R Natural Killer/T-Cell Lymphoma failure to Peg-ASP-based regimen by pathology and history; 3. Adequate hematologic and hepatic-renal function: Hemoglobin >=9 g/dl, Absolute neutrophil count >=1.5*10^9/L, Platelet count >=100*10^9/L, ALT 1.5cm in its largest dimension on CT scan; 5. Adequate cardiopulmonary function, no other serious disease; 6. The Pregnancy test of blood or urine is negative for women of reproductive potential. All patients agree to use adequate methods of contraception during the treatment period and until >= 12 months after the last chemotherapy; 7. Ability and willingness to comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1)NK cell leukemia; 2) accompanied by hemophagocytic syndrome; 3) central nervous system involvement or central nervous system NK/T cell lymphoma; 4) patients who have previously received allogeneic organ transplantation or need long-term application of anti-rejection drugs; 5) participating in other clinical studies, or less than 4 weeks after the last treatment; 6) autologous stem cell transplantation was performed within 90 days before the study started; Or had major surgery within 4 weeks; Or receive radiotherapy within the previous 3 months; 7) received live vaccine within 4 weeks before the study; 8) patients with previous interstitial lung disease; 9) patients who have received other checkpoint inhibitors, such as PD1 monoclonal antibody, pd-l1 monoclonal antibody and CTLA4 monoclonal antibody; 10) patients with drug allergy or metabolic disorder to the drugs in this program; 11) those who refuse to adopt reliable contraceptive methods during pregnancy and lactation or the right age; 12) any uncontrollable medical diseases (including uncontrolled diabetes, severe heart, lung, liver and kidney insufficiency); 13) patients who need systemic glucocorticoid therapy or other immunosuppressive therapy for other diseases within 2 weeks before treatment; 14) accompanied by active infection, such as tuberculosis; 15) contraindications to chemotherapy; 16) previous medical history of other malignant tumors; 17) mental disorder, incapacity or limited capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR;PR;SD; | — |
Secondary
| Measure | Time frame |
|---|---|
| OR;OS;PFS; | — |
Countries
China
Contacts
Public ContactLiling Zhang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed